À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉ磨×ܲ¿£º¶«¾© £¬CEO£ºÄÚÌÙÇç·ò £¬Ï³ơ°À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¡±£©ºÍÉú»¯Ñ§¹¤ÒµÖêʽ»áÉ磨×ܲ¿£º¶«¾© £¬×ܲãºË®¹È½¨ £¬¡°Éú»¯Ñ§¡±£©½üÈÕÐû²¼ £¬Á½¼Ò¹«Ë¾ÒѾÍÉú»¯Ñ§Ê×´´µÄ¹ÇÊàŦÑ×ÖÎÁƼÁSI-613£¨Ë«ÂÈ·ÒËá½áºÏ͸Ã÷ÖÊËáÄÆ£©ÔÚº«¹úµÄÁªºÏÉÏÊÐÇ©¶©ÐÒé¡£ÕâÊÇ×ÔÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍÉú»¯Ñ§ÓÚ2020Äê4ÔÂ1ÈÕ¾ÍSI-613ÔÚÖйúµÄÅäºÏ¿ª·¢ºÍÁªºÏÉÏÊÐÇ©ÊðÐÒéÒÔÀ´ £¬µÞ½áÁªºÏÉÏÊÐÐÒéµÄµÚ¶þ¸ö¹ú¼Ò¡£
ƾ¾Ý¸ÃÐÒé £¬Eisai Korea Inc.£¨À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾×Ó¹«Ë¾£©½«»ñµÃSI-613ÔÚº«¹úµÄ¶À¼ÒÉÏÊÐȨ £¬²¢ÉêÇëÆäÖÆÔìºÍÉÏÊÐÐí¿É¡£»ñÅúºó £¬Éú»¯Ñ§½«ÏòÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¹©Ó¦²úÎï £¬¶øÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÂôÁ¦·ÖÏú¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÏòÉú»¯Ñ§Ö§¸¶Ô¤¸¶¿î £¬²¢µ½´ïÏúÊÛÀï³Ì±®¡£
¹ÇÊàŦÑ×ÊÇÒ»ÖÖÓÉÀÏ»¯ºÍÆäËûÒòËص¼ÖµÄÊàŦÈí¹ÇËðÉËÒýÆðµÄ¼²²¡ £¬Òý·¢Ñ×Ö¢ºÍÌÛÍ´ £¬´Ó¶øµ¼ÖÂÉú»îÖÊÁ¿£¨QOL£©Ï½µ¡£Ï¥¹ÇÊàŦÑ×ÊÇÆä¼²²¡ÖÐ×î³£¼ûµÄ²¡ÀýÖ®Ò» £¬º«¹úÏ¥¹ÇÊàŦÑ×»¼ÕßµÄÈËÊýÔ¤¼ÆԼΪ320Íò¡£*1Ô¤¼ÆËæ×ÅÈË¿ÚÀÏÁ仯 £¬¸ÃÊý×Ö½«¼ÌÐøÔö¼Ó¡£
SI-613ÊÇÓÉÉú»¯Ñ§ÀûÓÃÆäרÓÐÒ©Îï½áºÏ¼¼Êõ½«Í¸Ã÷ÖÊËáºÍË«ÂÈ·ÒËᣨһÖÖ¿¹Ñ×Ò©Î»¯Ñ§½áºÏ¶ø³ÉµÄË«ÂÈ·ÒËá½áºÏ͸Ã÷ÖÊËáÄÆ¡£ÕâÖÖÎïÖʾßÓÐË«ÂÈ·ÒËáµÄֹʹºÍ¿¹Ñ××÷Óà £¬³ý͸Ã÷ÖÊËáÄƵÄÊàŦ¹¦Ð§¸ÄÉÆ×÷ÓÃÍâ £¬»¹Ö¼ÔÚͨ¹ýÊÍҩϵͳ*3Æðµ½»ºÊÍ×÷ÓÃ*2¡£Òò´Ë £¬Ô¤¼ÆSI-613¿É¿ìËÙÇÒÁ¬Ðø¼õÇáÓë¹ÇÊàŦÑ×Ïà¹ØµÄÌÛÍ´ºÍÑ×Ö¢¡£
ƾ¾Ý¸ÃÐÒé £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö¼ÔÚͨ¹ýÀûÓÃÆ享¹úÒµÎñ»ñµÃµÄ֪ʶºÍÍøÂç £¬Âú×ãÏ¥¹ÇÊàŦÑ×»¼ÕßδµÃµ½Âú×ãµÄÒ½ÁÆÐèÇó¡£Éú»¯Ñ§½«Í¨¹ýÀûÓÃÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄº«¹úÒµÎñ»ùµØ £¬Ñ°ÇóÔÚº«¹úʵÏÖSI-613¼ÛÖµµÄ×î´ó»¯¡£
Á½¼Ò¹«Ë¾½«Í¨¹ýSI-613µÄÉÌÒµ»¯ £¬ÔÚº«¹úÌṩÖÎÁÆÏ¥¹ÇÊàŦÑ×µÄÐÂÖÎÁÆ·½°¸ £¬ÒÔ´Ù½ø¸ÄÉÆ»¼ÕßµÄQOL¡£
<±à¼×¢ÊÍ>
1. ¹ØÓÚSI-613
SI-613ÊÇÓÉÉú»¯Ñ§ÀûÓÃÆä¶ÀÕ¼µÄÒ©Îï½áºÏ¼¼Êõ £¬½«Í¸Ã÷ÖÊËáºÍË«ÂÈ·ÒËᣨһÖÖ¿¹Ñ×Ò©Î»¯Ñ§½áºÏ¶ø³ÉµÄË«ÂÈ·ÒËá½áºÏ͸Ã÷ÖÊËáÄÆ¡£ÕâÖÖÎïÖʾßÓÐË«ÂÈ·ÒËáµÄֹʹºÍ¿¹Ñ××÷Óà £¬³ý͸Ã÷ÖÊËáÄƵÄÊàŦ¹¦Ð§¸ÄÉÆ×÷ÓÃÍâ £¬»¹Ö¼ÔÚͨ¹ýÊÍҩϵͳ*3Æðµ½»ºÊÍ×÷ÓÃ*2¡£Ô¤¼ÆSI-613¿É¿ìËÙÇÒÁ¬Ðø¼õÇáÓë¹ÇÊàŦÑ×£¨ÈçÏ¥ÊàŦ£©Ïà¹ØµÄÌÛÍ´ºÍÑ×Ö¢¡£ÁíÍâ £¬ÓÉÓÚͨ¹ý×¢É佫ÆäÖ±½Ó¸øÒ©ÖÁÊàŦǻÖÐ £¬ÈÏΪ˫ÂÈ·ÒËáÈ«Éí̻¶Á¿ºÍÒýÆðÈ«ÉíÒ©Îï²»Á¼·´Ó³µÄ·çÏյ͡£
2020Äê1ÔÂ6ÈÕ £¬Éú»¯Ñ§Ìá½»Ò»·ÝÐÂÒ©ÉêÇ루ϳơ°NDA¡±£© £¬ÉêÇëÅú×¼ÔÚÈÕ±¾ÖÆÔìºÍÉÏÊÐSI-613ÒÔÖÎÁƹÇÊàŦÑ×£¨Ï¥ÊàŦ¡¢÷ÅÊàŦºÍõ×ÊàŦ£©¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍÉú»¯Ñ§ÓÚ2020Äê4ÔÂ1ÈÕ¾ÍSI-613ÔÚÖйúµÄÅäºÏ¿ª·¢ºÍÉÏÊÐÁªÃËÇ©ÊðÐÒé¡£
2. ¹ØÓÚÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉç
À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉ罫ÆóҵʹÃü½ç˵Ϊ¡°ÎÒÃǽ«»¼Õß¼°¼ÒÊôµÄÀûÒæ·ÅÔÚÊ×λ £¬ÎªÌáÉýÆ丣ìí×ö³öТ¾´¡± £¬¼´ÎªÌåÌùÈËÀཡ¿µ£¨hhc£©ÀíÄî¡£±é²¼È«ÇòµÄÑз¢»ú¹¹¡¢Éú²ú»ùµØºÍÓªÏúÁ¥Êô¹«Ë¾×ܹ²ÓµÓнü10,000ÃûÔ±¹¤¡£ÎÒÃÇŬÁ¦Êµ¼ùhhcÀíÄî £¬Í¨¹ýÌṩ´´Ð²úÎïÂú×ã´ýÂú×ãµÄÒ½ÁÆÐèÇó £¬ÌرðÊÇÔÚÖ×ÁöѧºÍÉñ¾Ñ§ÁìÓò¡£×÷Ϊһ¼ÒÈ«ÇòÖÆÒ©¹«Ë¾ £¬ÎÒÃǵÄʹÃüÊÇͨ¹ýÓëÖ÷ÒªÀûÒæÏà¹Ø·½ºÏ×÷ £¬¸ÄÉÆÉú³¤Öйú¼ÒºÍÐÂÐ˹ú¼ÒµÄÒ©Æ·»ñÈ¡ÇþµÀ £¬´Ó¶øʹÊÀ½ç¸÷µØµÄ»¼ÕßÊÜÒæ¡£
ÓûÁ˽â¸ü¶àÓйØÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉçµÄÐÅÏ¢ £¬Çë·ÃÎÊhttps://www.eisai.com
3. ¹ØÓÚÉú»¯Ñ§¹¤ÒµÖêʽ»áÉç
Éú»¯Ñ§¹¤ÒµÖêʽ»áÉçÊÇÒ»¼ÒÑз¢ÐÍÖÆÒ©¹«Ë¾ £¬×¨×¢ÓÚÌÇ¿Æѧ×÷ΪרҵÁìÓò¡£×Ô1947Ä꽨Á¢ÒÔÀ´ £¬Éú»¯Ñ§Ò»Ö±×¨×¢ÓÚÌÇ¿ÆѧµÄ¿ÉÄÜÐÔ £¬²¢ÔڹǿƼ²»¼ºÍÑۿƼ²²¡ÁìÓò¿ª·¢Ô´´ÇÒÓÐÒæµÄÒ©Îï²úÎïºÍÒ½ÁÆÆ÷е¡£ÔÚÆæÌØÒµÎñģʽ£¨¼´×¨×¢ÓÚÑз¢ºÍÖÆÔì £¬¶øÎÞÄÚ²¿Ò©Æ·ÏúÊÛ²¿ÃÅ£©Ï £¬Éú»¯Ñ§Í¨¹ýÓëÔÚÌض¨¹ú¼ÒºÍ²úÎïÁìÓò¾ßÓÐÓÅÊƵĹ«Ë¾ºÏ×÷ £¬ÔÚÈ«Çò·¶Î§ÄÚ½«²úÎïÉÏÊÐ £¬ÎªÈ«ÊÀ½çÈËÃñµÄ½¡¿µºÍ³äʵµÄÉú»î×ö³öТ¾´¡£
ÓûÁ˽â¸ü¶àÓйØÉú»¯Ñ§¹¤ÒµÖêʽ»áÉçµÄÐÅÏ¢ £¬Çë·ÃÎÊhttps://www.seikagaku.co.jp/en/
²Î¿¼Îļþ£º
*1: For the estimated data regarding the number of patients with knee osteoarthritis
¡¤??Vital Data – Korea Statistical Information Service, URL:http://kosis.kr/index/index.do
¡¤? Changes in the number of patients – Healthcare Bigdata Hub, URL:https://opendata.hira.or.kr/home.do
*2: Sustained release is a gradual release of the active pharmaceutical ingredients of a drug to achieve a sustained therapeutic effect.
*3: Drug delivery system (DDS) is a technology for the controlled release, targeting, and absorption improvement of drugs.
